101 related articles for article (PubMed ID: 7751433)
1. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
Gupta SK; Kunka RL; Metz A; Lloyd T; Rudolph G; Perel JM
J Clin Pharmacol; 1995 Feb; 35(2):202-7. PubMed ID: 7751433
[TBL] [Abstract][Full Text] [Related]
2. Alosetron does not affect the visceral perception of gastric distension in healthy subjects.
Zerbib F; Bruley des Varannes S; Oriola RC; McDonald J; Isal JP; Galmiche JP
Aliment Pharmacol Ther; 1994 Aug; 8(4):403-7. PubMed ID: 7986965
[TBL] [Abstract][Full Text] [Related]
3. Effect of alosetron on theophylline pharmacokinetics.
Koch KM; Ricci BM; Hedayetullah NS; Jewell D; Kersey KE
Br J Clin Pharmacol; 2001 Nov; 52(5):596-600. PubMed ID: 11736869
[TBL] [Abstract][Full Text] [Related]
4. Effect of alosetron on the pharmacokinetics of alprazolam.
D'Souza DL; Levasseur LM; Nezamis J; Robbins DK; Simms L; Koch KM
J Clin Pharmacol; 2001 Apr; 41(4):452-4. PubMed ID: 11304902
[TBL] [Abstract][Full Text] [Related]
5. Effect of alosetron on the pharmacokinetics of fluoxetine.
D'Souza DL; Dimmitt DC; Robbins DK; Nezamis J; Simms L; Koch KM
J Clin Pharmacol; 2001 Apr; 41(4):455-8. PubMed ID: 11304903
[TBL] [Abstract][Full Text] [Related]
6. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and clinical experience with alosetron.
Camilleri M
Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study.
Bearcroft CP; André EA; Farthing MJ
Aliment Pharmacol Ther; 1997 Dec; 11(6):1109-14. PubMed ID: 9663837
[TBL] [Abstract][Full Text] [Related]
10. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
[TBL] [Abstract][Full Text] [Related]
11. Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.
Miranda A; Peles S; McLean PG; Sengupta JN
Pain; 2006 Dec; 126(1-3):54-63. PubMed ID: 16844296
[TBL] [Abstract][Full Text] [Related]
12. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
Nayak RK; Doose DR; Nair NP
J Clin Pharmacol; 1987 Feb; 27(2):144-50. PubMed ID: 3680566
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Chang WH; Lam YW; Jann MW; Chen H
Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
[TBL] [Abstract][Full Text] [Related]
15. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.
Barbhaiya RH; Shukla UA; Greene DS; Breul HP; Midha KK
J Clin Psychopharmacol; 1996 Feb; 16(1):26-34. PubMed ID: 8834415
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
17. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
Koch K; Campanella C; Baidoo CA; Manzo JA; Ameen VZ; Kersey KE
Dig Dis Sci; 2004 Aug; 49(7-8):1244-9. PubMed ID: 15387353
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
20. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
